Low Testosterone and Risk of Biochemical Recurrence and Poorly Differentiated Prostate Cancer at Radical Prostatectomy

Urology

Volumn 72, Issue 6, 2008, Pages 1240-1245

  Lane, Brian R ^a   Stephenson, Andrew J ^a   Magi Galluzzi, Cristina ^a   Lakin, Milton M ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

ADULT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TESTOSTERONE BLOOD LEVEL; TUMOR VOLUME;

AGED; CELL DIFFERENTIATION; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES; RISK; TESTOSTERONE;

EID: 56449126893     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.06.001     Document Type: Article

References (19)

1. Nelson J.B. Hormone therapy for prostate cancer. In: Wein A.J., Kavoussi L.R., Novick A.C., et al. (Eds). Campbell-Walsh Urology. 9th ed. (2007), WB Saunders, Philadelphia 3082-3100
2. Morgentaler A., Bruning III C.O., and DeWolf W.C. Occult prostate cancer in men with low serum testosterone levels. JAMA 276 (1996) 1904-1906
3. Hoffman M.A., DeWolf W.C., Morgentaler A., et al. Serum free testosterone a marker for high-grade prostate cancer?. J Urol 163 (2000) 824-827
4. Massengill J.C., Sun L., Moul J.W., et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169 (2003) 1670-1675
5. Isom-Batz G., Bianco Jr. F.J., Kattan M.W., et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 173 (2005) 1935-1937
6. Teloken C., Da Ross C., Caraver F., et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: Hypogonadism represents bad prognosis in prostate cancer. J Urol 174 (2005) 2178-2180
7. San Francisco I.F., Regan M.M., Dewolf W.C., et al. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 175 (2006) 1341 1345-1346
8. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
9. Banach-Petrosky W., Jessen W.J., Ouyang X., et al. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res 67 (2007) 9089-9096
10. Rose R.M., Kreuz L.E., Holaday J.W., et al. Diurnal variation of plasma testosterone and cortisol. J Endocrinol 54 (1972) 177-178
11. Piro C., Fraioli F., Sciarra F., et al. Circadian rhythm of plasma testosterone, cortisol and gonadotropins in normal male subjects. J Steroid Biochem 4 (1973) 321-329
12. Klein E.A., Kupelian P.A., Tuason L., et al. Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy. Urology 51 (1998) 766-773
13. Derweesh I.H., Kupelian P.A., Zippe C., et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 22 (2004) 300-306
14. Renshaw A.A., Chang H., and D'Amico A.V. Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. Am J Clin Pathol 107 (1997) 704-708
15. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23 (2005) 7005-7012
16. Imamoto T., Suzuki H., Akakura K., et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 48 (2001) 573-578
17. Yamamoto S., Yonese J., Kawakami S., et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 52 (2007) 696-701
18. Lucia M.S., Epstein J.I., Goodman P.J., et al. Finasteride and high-grade PC in the prostate cancer prevention trial. J Natl Cancer Inst 99 (2007) 1375-1383
19. Roddam A.W., Allen N.E., Appleby P., et al., Endogenous Hormones, Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100 (2008) 170-183